Company intelligence / Profile preview

Funxional Therapeutics

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

FX125L, the company’s lead candidate, demonstrated an excellent safety, tolerability, and pharmacokinetic profile in Phase I trials and was advanced into Phase II trials for inflammatory diseases including asthma and COPD prior to acquisition; clinical differentiation and commercial potential highlighted but no commercial results due to acquisition.

Therapeutic areas: ImmunologyPulmonologyDermatologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Ipsen (academic/technology collaboration)Boehringer Ingelheim (acquirer/partner for portfolio)

Beyond the preview

Go deeper on Funxional Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Funxional Therapeutics.

Explore the full profile